Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Europe Oral Anti-Diabetic Drug MARKET 2026-2031 - Rising Diabetes Prevalence Drives Market Growth

globenewswire.com
NVO Novo Nordisk is listed as a key company in the competitive landscape of the Europe oral anti-diabetic drug market. The article does not provide specific sentiment towards the company but discusses the market dynamics it operates within, including growth drivers and restraints. LLY Eli Lilly is mentioned as a key player in the Europe oral anti-diabetic drug market. The article does not offer specific sentiment but places it within the context of market competition and evolving treatment trends. AZN AstraZeneca is identified as a company within the competitive landscape of the Europe oral anti-diabetic drug market. The article does not provide specific sentiment but includes it in the context of market analysis. JNJ Johnson & Johnson is listed as a company in the competitive landscape of the Europe oral anti-diabetic drug market. The article does not provide specific sentiment towards the company but includes it in the overall market analysis. MRK Merck & Co. is mentioned as a key company in the competitive landscape of the Europe oral anti-diabetic drug market. The article does not offer specific sentiment but includes it in the context of market competition and evolving treatment trends. SNY Sanofi is listed as a company within the competitive landscape of the Europe oral anti-diabetic drug market. The article does not provide specific sentiment but includes it in the overall market analysis. PFE Pfizer is mentioned as a key player in the competitive landscape of the Europe oral anti-diabetic drug market. The article does not provide specific sentiment but places it within the context of market competition and evolving treatment trends. BMY Bristol Myers Squibb is listed as a company in the competitive landscape of the Europe oral anti-diabetic drug market. The article does not provide specific sentiment but includes it in the overall market analysis. NOV Novartis is mentioned as a key company in the competitive landscape of the Europe oral anti-diabetic drug market. The article does not offer specific sentiment but includes it in the context of market competition and evolving treatment trends. TEVA Teva Pharmaceuticals is listed as a company in the competitive landscape of the Europe oral anti-diabetic drug market. The article does not provide specific sentiment but includes it in the overall market analysis. VTRS Viatris is mentioned as a key company in the competitive landscape of the Europe oral anti-diabetic drug market. The article does not offer specific sentiment but includes it in the context of market competition and evolving treatment trends.

Europe Oral Anti-Diabetic Drug MARKET 2026-2031 - Rising Diabetes Prevalence Drives Market Growth Dublin, Aug. 25, 2026 (GLOBE NEWSWIRE) -- The "Europe Oral Anti-Diabetic Drug - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)" has been added to ResearchAndMarkets.com's offering.

Europe Oral Anti-Diabetic Drug Market to Reach USD 9.2 Billion by 2031

The Europe oral anti-diabetic drug market was valued at USD 7.61 billion in 2025 and is expected to increase from USD 7.86 billion in 2026 to USD 9.2 billion by 2031. The market is forecast to record a compound annual growth rate of 3.22% between 2026 and 2031, supported by the increasing prevalence of type 2 diabetes, rising obesity rates, population ageing and continued innovation in diabetes treatment.

Rising Type 2 Diabetes and Obesity Rates Support Market Growth

Lifestyle changes and demographic trends continue to increase the number of adults living with diabetes across Europe. The International Diabetes Federation projects that the global diabetic population will reach 784 million by 2045, creating sustained demand for effective glucose-lowering medications and therapies that address related cardiovascular and renal risks.

Country-level trends also demonstrate strong demand for advanced metabolic treatments. Spain's weight-management market grew 65% to EUR 484 million in 2024, while Portugal recorded sales approaching EUR 20 million in early 2025 despite limited reimbursement. Private purchases have also increased in Italy as patients seek newer treatment options. These developments show how the overlap between obesity and type 2 diabetes is expanding opportunities within the Europe oral anti-diabetic drug market.

Cardio-Renal Benefits Accelerate SGLT-2 Inhibitor Adoption

European label expansions are strengthening demand for SGLT-2 inhibitors. The European Commission's 2024 approval of empagliflozin for chronic kidney disease expanded the class beyond glucose management and reinforced its role in cardio-renal care. With approximately 47 million Europeans living with chronic kidney disease, the potential patient population has widened considerably.

Clinical evidence indicates that SGLT-2 inhibitors can improve HbA1c, body mass index and systolic blood pressure while reducing hospitalisations for heart failure. These outcomes are increasing physician confidence and supporting wider use among patients with diabetes, cardiovascular disease and impaired kidney function. As treatment guidelines place greater emphasis on complication prevention, the class is expected to deliver one of the fastest growth rates in the European market.

High Treatment Costs Remain a Key Market Restraint

Pricing and reimbursement restrictions continue to limit access to novel incretin and SGLT-2 therapies. Annual costs for some GLP-1 treatments can exceed USD 16,000, creating pressure on public healthcare budgets. Germany excludes weight-loss indications from statutory reimbursement, France removed Wegovy from its positive reimbursement list in late 2023, and access in the United Kingdom has been limited through specialist obesity services during phased implementation.

Payer caution persists even as cardiovascular outcomes data continue to improve. Approximately 76 million obese adults without diabetes across the five largest European markets may remain unable to access treatment because of affordability or reimbursement barriers. Additional market considerations include the adoption of oral semaglutide, e-prescription mandates supporting online pharmacy growth and safety monitoring related to SGLT-2-associated euglycaemic diabetic ketoacidosis.

Biguanides Retain Leadership as Innovative Drug Classes Gain Share

Biguanides accounted for 38.05% of prescriptions in 2025, supported by low treatment costs, established clinical familiarity and their continued role in first-line diabetes care. However, SGLT-2 inhibitors are projected to expand at a 3.72% compound annual growth rate through 2031 as physicians increasingly prioritise treatments with cardiovascular and renal benefits.

Sulfonylurea use is declining in parts of Southern Europe because of hypoglycaemia concerns and changing clinical guidelines. DPP-4 inhibitors continue to serve patients who may not be suitable for SGLT-2 or GLP-1 therapies, while alpha-glucosidase inhibitors and thiazolidinediones remain limited to specific treatment needs. Emerging therapies, including dual GIP/GLP-1 agonists, are also influencing prescribing decisions as clinical studies demonstrate substantial improvements in glucose control.

Ageing Population Creates New Treatment Opportunities

Adults represented 66.35% of oral anti-diabetic drug use in Europe during 2025, reflecting the substantial burden of type 2 diabetes among working-age patients. The geriatric segment, however, is expected to grow at a faster compound annual rate of 3.86% through 2031. Updated treatment guidelines increasingly recommend therapies based on cardiovascular, renal and metabolic complications rather than age alone.

Demand among older patients is shifting toward medicines associated with a lower risk of hypoglycaemia, including SGLT-2 inhibitors and GLP-1 receptor agonists, although renal-function monitoring remains important. Digital therapeutics and artificial intelligence-enabled care models may further improve medication management and glycaemic outcomes. Together, these trends are expected to support steady expansion of the Europe oral anti-diabetic drug market through 2031.

Key Topics Covered:

1 Introduction

1.1 Study Assumptions & Market Definition

1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

4.1 Market Overview

4.2 Market Drivers

4.2.1 Escalating Prevalence of Type-2 Diabetes & Obesity

4.2.2 EU-Wide Cardio-Renal Label Expansions For SGLT-2 Class

4.2.3 Uptake Of Oral GLP-1 (Semaglutide/Rybelsus)

4.2.4 E-Prescription Mandates Accelerating E-Pharmacy Channels

4.2.5 Upcoming Patent Cliffs Unlocking Low-Cost Generics

4.2.6 AI-Driven Poly-Pharmacy Optimisation in Primary Care

4.3 Market Restraints

4.3.1 High List Prices of Novel Incretin & SGLT-2 Therapies

4.3.2 Safety Signals: SGLT-2-Induced Euglycaemic DKA Cases

4.3.3 API Supply-Chain Fragility Within Europe & India

4.3.4 Therapeutic Inertia Among General Practitioners

4.4 Regulatory Landscape

4.5 Porters Five Forces Analysis

4.5.1 Bargaining Power of Suppliers

4.5.2 Bargaining Power of Consumers

4.5.3 Threat of New Entrants

4.5.4 Threat of Substitute Products and Services

4.5.5 Intensity of Competitive Rivalry

5 Market Size & Growth Forecasts (Value, USD)

5.1 By Drug Class

5.1.1 Biguanides

5.1.2 Sulfonylureas

5.1.3 Meglitinides

5.1.4 Thiazolidinediones

5.1.5 Alpha-Glucosidase Inhibitors

5.1.6 DPP-4 Inhibitors

5.1.7 SGLT-2 Inhibitors

5.1.8 Others

5.2 By Age Group

5.2.1 Adults

5.2.2 Pediatric

5.2.3 Geriatric

5.3 By Diabetes Type

5.3.1 Type 1 Diabetes

5.3.2 Type 2 Diabetes

5.4 By Distribution Channel

5.4.1 Hospital Pharmacies

5.4.2 Retail Pharmacies

5.4.3 Online Pharmacies

5.5 By Geography

5.5.1 Germany

5.5.2 United Kingdom

5.5.3 France

5.5.4 Italy

5.5.5 Spain

5.5.6 Rest of Europe

6 Competitive Landscape

6.1 Market Concentration

6.2 Market Share Analysis

6.3 Company Profiles (includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products & Services, and Recent Developments)

6.3.1 Novo Nordisk

6.3.2 Eli Lilly

6.3.3 Boehringer Ingelheim

6.3.4 AstraZeneca

6.3.5 Johnson & Johnson

6.3.6 Merck & Co.

6.3.7 Sanofi

6.3.8 Takeda

6.3.9 Pfizer

6.3.10 Bristol Myers Squibb

6.3.11 Astellas Pharma

6.3.12 Novartis

6.3.13 Teva Pharmaceuticals

6.3.14 Viatris

6.3.15 Sun Pharma

6.3.16 Recordati

6.3.17 Servier

6.3.18 Lupin

6.3.19 Zentiva

7 Market Opportunities & Future Outlook

7.1 White-space & Unmet-Need Assessment

For more information about this report visit https://www.researchandmarkets.com/r/6gtklb

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.